S
Shirin Strohmeier
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 65
Citations - 5873
Shirin Strohmeier is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Virus & Hemagglutinin (influenza). The author has an hindex of 18, co-authored 53 publications receiving 3361 citations. Previous affiliations of Shirin Strohmeier include University of Natural Resources and Life Sciences, Vienna & Crips.
Papers
More filters
Journal ArticleDOI
A serological assay to detect SARS-CoV-2 seroconversion in humans.
Fatima Amanat,Daniel Stadlbauer,Shirin Strohmeier,Shirin Strohmeier,Thi H. O. Nguyen,Veronika Chromikova,Meagan McMahon,Kaijun Jiang,Guha Asthagiri Arunkumar,Denise Jurczyszak,Jose Polanco,Maria Bermudez-Gonzalez,Giulio Kleiner,Teresa Aydillo,Lisa Miorin,Daniel S. Fierer,Luz Amarilis Lugo,Erna Milunka Kojic,Jonathan Stoever,Sean T. H. Liu,Charlotte Cunningham-Rundles,Philip L. Felgner,Thomas M. Moran,Adolfo García-Sastre,Daniel Caplivski,Allen C. Cheng,Katherine Kedzierska,Olli Vapalahti,Jussi Hepojoki,Jussi Hepojoki,Viviana Simon,Florian Krammer +31 more
TL;DR: A serological enzyme-linked immunosorbent assay for the screening and identification of human SARS-CoV-2 seroconverters and can be adjusted to detect different antibody types in serum and plasma.
Journal ArticleDOI
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months.
Ania Wajnberg,Fatima Amanat,Adolfo Firpo,Deena R. Altman,Mark J. Bailey,Mayce Mansour,Meagan McMahon,Philip Meade,Damodara Rao Mendu,Kimberly Muellers,Daniel Stadlbauer,Kimberly Stone,Shirin Strohmeier,Viviana Simon,Judith A. Aberg,David Reich,Florian Krammer,Carlos Cordon-Cardo +17 more
TL;DR: The vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein, and titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2.
Journal ArticleDOI
SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup.
Daniel Stadlbauer,Fatima Amanat,Veronika Chromikova,Kaijun Jiang,Shirin Strohmeier,Shirin Strohmeier,Guha Asthagiri Arunkumar,Jessica Tan,Disha Bhavsar,Christina Capuano,Ericka Kirkpatrick,Philip Meade,Ruhi Nichalle Brito,Catherine Teo,Meagan McMahon,Viviana Simon,Florian Krammer +16 more
TL;DR: A detailed protocol for expression of antigens derived from the spike protein of SARS‐CoV‐2 that can serve as a substrate for immunological assays, as well as a two‐stage serological enzyme‐linked immunosorbent assay (ELISA) can be used for research studies and for testing in clinical laboratories.
Posted ContentDOI
A serological assay to detect SARS-CoV-2 seroconversion in humans
Fatima Amanat,Daniel Stadlbauer,Shirin Strohmeier,Shirin Strohmeier,Thi H. O. Nguyen,Veronika Chromikova,Meagan McMahon,Kaijun Jiang,Guha Asthagiri Arunkumar,Denise Jurczyszak,Jose Polanco,Maria Bermudez-Gonzalez,Giulio Kleiner,Teresa Aydillo,Lisa Miorin,Daniel S. Fierer,Luz Amarilis Lugo,Erna Milunka Kojic,Jonathan Stoever,Sean T. H. Liu,Charlotte Cunningham-Rundles,Philip L. Felgner,Thomas M. Moran,Adolfo García-Sastre,Daniel Caplivski,Allen C. Cheng,Katherine Kedzierska,Olli Vapalahti,Jussi Hepojoki,Jussi Hepojoki,Viviana Simon,Florian Krammer +31 more
TL;DR: Serological assays are of critical importance to determine seroprevalence in a given population, define previous exposure and identify highly reactive human donors for the generation of convalescent serum as therapeutic.
Journal ArticleDOI
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Dorottya Laczkó,Michael J. Hogan,Sushila A. Toulmin,Philip Hicks,Katlyn Lederer,Brian T. Gaudette,Diana Castaño,Diana Castaño,Fatima Amanat,Hiromi Muramatsu,Thomas H. Oguin,Amrita Ojha,Lizhou Zhang,Zekun Mu,Robert Parks,Tomaz B. Manzoni,Brianne Roper,Shirin Strohmeier,István Tombácz,Leslee Arwood,Raffael Nachbagauer,Katalin Karikó,Jack Greenhouse,Laurent Pessaint,Maciel Porto,Tammy Putman-Taylor,Amanda Strasbaugh,Tracey Ann Campbell,Paulo J.C. Lin,Ying K. Tam,Gregory D. Sempowski,Michael Farzan,Hyeryun Choe,Kevin O. Saunders,Barton F. Haynes,Hanne Leth Andersen,Laurence C. Eisenlohr,Laurence C. Eisenlohr,Drew Weissman,Florian Krammer,Paul Bates,David Allman,Michela Locci,Norbert Pardi +43 more
TL;DR: It is suggested that the nucleoside-modified mRNA-LNP vaccine platform can induce robust immune responses and is a promising candidate to combat COVID-19.